HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration M Mielcarek, C Landles, A Weiss, A Bradaia, T Seredenina, L Inuabasi, ... PLoS biology 11 (11), e1001717, 2013 | 180 | 2013 |
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease M Mielcarek, CL Benn, SA Franklin, DL Smith, B Woodman, PA Marks, ... PloS one 6 (11), e27746, 2011 | 171 | 2011 |
Gene therapy advances: a meta-analysis of AAV usage in clinical settings HKE Au, M Isalan, M Mielcarek Frontiers in medicine 8, 809118, 2022 | 149 | 2022 |
Skeletal muscle pathology in Huntington's disease D Zielonka, I Piotrowska, JT Marcinkowski, M Mielcarek Frontiers in physiology 5, 380, 2014 | 130 | 2014 |
HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements M Mielcarek, D Zielonka, A Carnemolla, JT Marcinkowski, F Guidez Frontiers in cellular neuroscience 9, 42, 2015 | 103 | 2015 |
Dysfunction of the CNS-heart axis in mouse models of Huntington's disease M Mielcarek, L Inuabasi, MK Bondulich, T Muller, GF Osborne, ... PLoS genetics 10 (8), e1004550, 2014 | 92 | 2014 |
Update on Huntington's disease: advances in care and emerging therapeutic options D Zielonka, M Mielcarek, GB Landwehrmeyer Parkinsonism & related disorders 21 (3), 169-178, 2015 | 88 | 2015 |
Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease CL Benn, R Butler, L Mariner, J Nixon, H Moffitt, M Mielcarek, B Woodman, ... PLoS One 4 (6), e5747, 2009 | 74 | 2009 |
Identification of 6-furfuryladenine (kinetin) in human urine J Barciszewski, M Mielcarek, M Stobiecki, G Siboska, BFC Clark Biochemical and biophysical research communications 279 (1), 69-73, 2000 | 74 | 2000 |
VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage Mielcarek, M., Gunther, S., Kruger, M., Braun, T. Mechanism of Development 119, S269-S274, 2002 | 72* | 2002 |
HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy M Mielcarek, M Toczek, CJLM Smeets, SA Franklin, MK Bondulich, ... PLoS genetics 11 (3), e1005021, 2015 | 69 | 2015 |
VITO‐1 is an essential cofactor of TEF1‐dependent muscle‐specific gene regulation S Günther, M Mielcarek, M Krüger, T Braun Nucleic acids research 32 (2), 791-802, 2004 | 65 | 2004 |
Huntington's disease is a multi-system disorder M Mielcarek Rare Diseases 3 (1), e1058464, 2015 | 62 | 2015 |
Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice C Agustín-Pavón, M Mielcarek, M Garriga-Canut, M Isalan Molecular Neurodegeneration 11 (64), 2016 | 57 | 2016 |
Neuro-cardio mechanisms in Huntington’s disease and other neurodegenerative disorders BJ Critchley, M Isalan, M Mielcarek Frontiers in Physiology 9, 337975, 2018 | 42 | 2018 |
An impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington's disease related cardiomyopathy M Toczek, D Zielonka, P Zukowska, JT Marcinkowski, E Slominska, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1862 (11 …, 2016 | 41 | 2016 |
VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development M Mielcarek, I Piotrowska, A Schneider, S Günther, T Braun Gene Expression Patterns 9 (3), 129-137, 2009 | 38 | 2009 |
HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo M Mielcarek, T Seredenina, MP Stokes, GF Osborne, C Landles, ... PloS one 8 (11), e80849, 2013 | 33 | 2013 |
The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model M Mielcarek, MK Bondulich, L Inuabasi, SA Franklin, T Muller, GP Bates PLoS One 9 (9), e108961, 2014 | 29 | 2014 |
A shared mechanism of muscle wasting in cancer and Huntington’s disease M Mielcarek, M Isalan Clinical and translational medicine 4, 1-4, 2015 | 25 | 2015 |